-
- Jan 21, 2021
Antimalarials adherence lowers risk of death in systemic lupus erythematosus
Patients with systemic lupus erythematosus (SLE) who adhered to antimalarials (AM) therapy lowered their risk of death by up to 71% compared to patients who did not adhere to AM therapy and 83% compared to those who discontinued AM, according to a study.
A total of 3062 individuals with SLE who were treated with AM were included and followed from t…
-
.jpeg)
- Jan 21, 2021
Sequential chemoradiation shows promise as adjuvant treatmen...
Sequential chemoradiation after radical hysterectomy in women with early-stage cervical cancer may a... -
- Jan 21, 2021
Pembrolizumab shows promise in advanced HCC
Pembrolizumab monotherapy demonstrated durable anti-tumor activity and promising overall survival in...
VIDEOS
- Jan 11, 2021
Biomarkers for pediatric lupus nephritis
-
Jan 11, 2021
The Pathology of Lupus Nephritis…
-
Jan 11, 2021
The Management of Lupus Nephritis…
-
Nov 19, 2020
Uncommon Interstitial Lung…
-
Nov 19, 2020
Interstitial Lung Disease with Dr…
-
Nov 19, 2020
Emerging Therapies for…
-
Nov 13, 2020
AAO: Management of Thyroid Eye…
Nov 13, 2020
AAO: Management of Thyroid Eye Disease
-
TEPEZZA x Horizon Therapeutics
Nov 13, 2020
-
What is DME?
Oct 14, 2020
-
Treating AMD Patients with New Technology
Oct 14, 2020
Conference Roundup
- Jan 20, 2021
Pembrolizumab shows promise in advanced HCC
Pembrolizumab monotherapy demonstrated durable anti-tumor activity and promising overall survival in patients with advanced hepatocellular carcinoma (HCC), according to study data presented at Gastrointestinal Cancers Symposium.
In…
Continuing Medical Education
-
NORD: Giant Cell (Session 1)
Mar 23, 2020
-
-
NORD: Spinal Muscular Atrophy
Mar 23, 2020
-
NORD: Pediatric Epilepsy
Mar 23, 2020
Journal Scan
- Jan 21, 2021
Antimalarials adherence lowers risk of death in systemic lupus erythematosus
Patients with systemic lupus erythematosus (SLE) who adhered to antimalarials (AM) therapy lowered their risk of death by up to 71% compared to patients who did not adhere to AM therapy and 83% compared to those who discontinued AM, according to a study.
…
Trending Topics
- Jan 18, 2021
FDA approves first treatment for newly diagnosed light chain (AL) amyloidosis
The U.S. Food and Drug Administration has approved daratumumab and hyaluronidase-fihj (Darzalex Faspro) in combination with bortezomib, cyclophosphamide, and dexamethasone (D-VCd) for the treatment of adult patients with newly diagnosed light chain (AL) amyloidosis. Daratumumab and…
Resources
-
Tools
- Find Zebra
- Genetic and Rare Diseases Information Center
- National Kidney Foundation
- National Organization for Rare Disorders (NORD)
- National Organization for Rare Disorders (NORD): Patient Assistance Programs
- NCATS Toolkit for Patient-Focused Therapy Development
- NCCN Guidelines
- NORD Online Physician Guides
- Orphan Products Clinical Trials Grants Program
- Orphanet
- Rare Diseases Registry Program